Posted on 25th November 2014
Popular in the US, Avastin is used for patients with age-related macular degeneration (AMD). It has been on the market for years, gone through all the testing and has been proven to be as effective as Lucentis, the NHS approved drug for the same condition. The difference is cost. Lucentis typically costs around £700 per treatment, compared to Avastin which is about £70. Yet red tape seems to be halting its use.
It is currently unlicensed in the UK so should anything go wrong with its use, the practitioner may not be legally covered. However, in times of austerity and it is perhaps time for the NHS to move forward and license its use.
28th January 2021
We’ve had several patients get in touch to say their children are complaining of sore eyes and headaches at the moment. Older children in particular, are spending many hours on screens whilst homesc...
Read more18th January 2021
We are saddened to inform you that at the end of last year we lost our founding partner, Murray McGrath, who many of you will have been treated by over the years. Cameron Optometry started out as W M ...
Read more07th January 2021
This page will have our latest information on the care we can provide during the COVID-19 pandemic. You can also find information on our Facebook page. LATEST UPDATE Thursday, 7 January, 2021 We are...
Read more16th December 2020
We are delighted to let you know that we have a new optometrist joining the practice in January. Alexandra Young is incredibly highly regarded and we are excited to welcome her to the team. In addi...
Read more